01—Abstract
Summary
Summary of the 10-K/A filed December 14, 2004. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. (REGN) reported its annual performance for the period ending December 30, 2003, with the filing made on December 13, 2004.
The company, a biopharmaceutical firm focused on discovering, developing, and commercializing treatments for serious medical conditions, is heavily invested in its pipeline of product candidates, including VEGF Trap for cancer and eye diseases, IL-1 Trap for rheumatoid arthritis, IL-4/13 Trap for asthma, and AXOKINE® for obesity. As of the reporting period, Regeneron had not yet generated any sales or profits from commercialized products, reflecting its early-stage development nature. The company's strategy centers on leveraging its scientific research and technology platforms to build an integrated biopharmaceutical business.
Significant collaboration agreements were highlighted, notably with Aventis for the VEGF Trap and a terminated collaboration with Novartis for the IL-1 Trap, alongside an ongoing collaboration with Procter & Gamble. These partnerships involve substantial upfront payments, milestone opportunities, and shared development expenses, indicating the capital-intensive nature of drug development and Regeneron's reliance on strategic alliances.
02—Key points
Key Highlights
- Regeneron is a biopharmaceutical company focused on developing treatments for serious medical conditions, with product candidates in various stages of clinical development, including VEGF Trap, IL-1 Trap, IL-4/13 Trap, and AXOKINE®.
- The company has not generated any sales or profits from commercialized products, underscoring its development-stage status.
- Significant collaboration agreements are in place, including a key partnership with Aventis for the VEGF Trap, which includes upfront payments, potential milestones totaling up to $360 million, and shared development costs.
- A collaboration with Novartis for the IL-1 Trap was announced as terminated, impacting future development plans and funding for that specific program.
- Research and development expenses were substantial, reaching $136.0 million in 2003, reflecting ongoing investment in its pipeline.
- The company reported a net loss of $107.5 million for 2003, consistent with its developmental stage.
- Regeneron's financial position showed a healthy cash and marketable securities balance of $366.6 million as of December 31, 2003, providing runway for ongoing operations.
03—Questions
Frequently Asked Questions
What are Regeneron's primary product candidates and their current development stage?
Regeneron has four main product candidates in clinical development: VEGF Trap for cancer and eye diseases (Phase I), IL-1 Trap for rheumatoid arthritis (Phase II), IL-4/13 Trap for asthma (Phase I), and AXOKINE® for obesity (Phase III). The company also has research programs in other areas like metabolic diseases and muscle atrophy.
What is the financial status of Regeneron as of December 2003?
As of December 31, 2003, Regeneron had total assets of $479.6 million, with $366.6 million in cash, cash equivalents, and marketable securities. The company reported a net loss of $107.5 million for the year, which is typical for a company in the drug development phase. Research and development expenses were $136.0 million.
What are the key collaborations Regeneron has in place?
Regeneron has a significant collaboration with Aventis for the VEGF Trap, which includes an $80 million upfront payment and potential milestone payments up to $360 million. The company also had a collaboration with Novartis for the IL-1 Trap, which has since been terminated by Novartis. An ongoing collaboration with Procter & Gamble focuses on therapeutic areas of interest to them, including muscle atrophy and fibrotic diseases.
What is Regeneron's revenue model at this stage?
Regeneron's revenue primarily comes from contract research and development payments, research progress payments from collaborators, and contract manufacturing revenue, mainly from a long-term agreement with Merck & Co. The company has not generated revenue from product sales as it has no commercialized products yet.
04—Continue